Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1238202 | 0.95 | CYP2D6 (0.43) | CYP2D6 | |
| SCHEMBL913008 | 0.95 | CYP2D6 (0.39) | CYP2D6 | |
| SCHEMBL11903954 | 0.94 | CYP2D6 (0.43) | CYP2D6 | |
| SCHEMBL1238426 | 0.90 | CYP2D6 (0.38) | CYP2D6 | |
| SCHEMBL1237574 | 0.90 | CYP2D6 (0.47) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL6897298 | 0.89 | — | — | |
| SCHEMBL6901626 | 0.89 | — | — | |
| SCHEMBL6897845 | 0.89 | — | — | |
| SCHEMBL6902582 | 0.89 | — | — | |
| SCHEMBL10872014 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409486-A1 | COMPOUND PRODUCING METHOD INCLUDING STEP OF ISOMERIZING ALPHA, BETA-UNSATURATED KETONE | KAO CORPORATION (JP) | 2024-12-12 | — | — | US | disclosed |
| CN-118103345-A | Method for producing compound comprising isomerization step of alpha, beta-unsaturated ketone | 花王株式会社 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023063030-A1 | COMPOUND PRODUCING METHOD INCLUDING STEP FOR ISOMERIZING α,β-UNSATURATED KETONE | 花王株式会社 | 2023-04-20 | — | — | WO | disclosed |
| EP-2487150-B1 | PROCESS FOR PRODUCING A LACTONE | KAO CORP (JP) | 2016-12-28 | — | — | EP | disclosed |
| EP-2266943-B1 | METHOD FOR PRODUCING OF 2-ALKYL-2-CYCLOALKEN-1-ONE | KAO CORP (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-8394994-B2 | Method for producing of 2-alkyl-2-cycloalken-1-one | KAO CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| EP-2487150-A1 | PROCESS FOR PRODUCING 2-ALKYLCYCLOALKANONE | Kao Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20110034722-A1 | METHOD FOR PRODUCING OF 2-ALKYL-2-CYCLOALKEN-1-ONE | KAO CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2266943-A1 | METHOD FOR PRODUCING OF 2-ALKYL-2-CYCLOALKEN-1-ONE | Kao Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409486-A1 | COMPOUND PRODUCING METHOD INCLUDING STEP OF ISOMERIZING ALPHA, BETA-UNSATURATED KETONE | CBR1, AKR1B1, AKR1C1 | CYP2D6 349/4885CA1 136/4885CA2 929/4885 |
| US-20110034722-A1 | METHOD FOR PRODUCING OF 2-ALKYL-2-CYCLOALKEN-1-ONE | PAOX, CYP1A1, ADH1A | CYP2D6 490/4885CA1 194/4885CA2 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.